RxDoctor Payments Data

Jameca Price, MD

Urogynecology and Reconstructive Pelvic Surgery · Tulsa, OKNPI 1780818575

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,606 of the $1,908 with a category attached, or 84.2%. 6 manufacturers reported payments, led by Coloplast at 55.6% of the total. Reporting peaked in 2024 at $525 and has fallen 78.2% since, to $115 in 2025.

$1,908in general payments, 2019–2025

Across 26 payments — averaging $73.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Medtronic$417
  • Axonics, Inc.$170
  • AbbVie$121
  • Intuitive Surgical$100
  • Applied Medical Resources Corporation$40

What the payments were for

  • Travel & lodging$28415%
  • Food & beverage$1,60684%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast9$1,060
Medtronic7$417
Axonics, Inc.2$170
AbbVie(2 entities)6$121
Intuitive Surgical1$100
Applied Medical Resources Corporation1$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$81,711
Medicare patients
102
Services billed
845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron91$46,819
GemtesaVibegron26$21,077
PremarinEstrogens, Conjugated16$7,162
Estradiol77$3,974
Trospium Chloride16$1,379
Solifenacin Succinate47$1,292
Tolterodine Tartrate ErTolterodine Tartrate14$433
Metronidazole25$189
Fluconazole14$112
Celecoxib11$74
Gabapentin17$66
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$55

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →